<DOC>
	<DOCNO>NCT00378625</DOCNO>
	<brief_summary>The primary goal study quantify benefit add artesunate amodiaquine treat patient uncomplicated P. falciparum malaria , low transmission area Colombia . The benefit assess term : - Efficacy - Tolerability - Time fever clearance - Time parasite clearance - Proportion gametocyte carrier</brief_summary>
	<brief_title>Efficacy , Effect Gametocytes Tolerability Addition Artesunate Amodiaquine Colombia</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1. pure P. falciparum infection 2. parasitaemia &gt; 500 &lt; 50,000 asexual parasites/μL ( subsequently low limit modify &gt; 250 asexual parasites/μL ) 3. age 1 65 year old 4. availability return followup 1 . Pregnancy 2. history allergy study drug 3. history take complete treatment antimalarial drug previous 72 hour sulphas , clindamycin tetracycline previous week 4. medical history untreated hypertension chronic heart , kidney liver disease 5. present danger sign severe malaria .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>